Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

LEIDEN, The Netherlands, Sept. 28, 2022.Pharming Group N.V. ( " Pharming " or " the Company " ) announces that the US Food and Drug Administration (FDA) has accepted for priority review its New Drug Application (NDA) for leniolisib, an oral, selective...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials